The risks of recurrence and death were reduced after atezolizumab treatment by 34% in stage II–IIIA NSCLC patients with ≥ 1% PD-L1 expression and by 21% in all stage II–IIIA NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.